Potential role for somatostatin analogues in breast cancer: rationale and description of an ongoing trial

Print
Published on Wednesday, 09 October 2013

Abstract

Somatostatin analogues such as octreotide have been shown in experimental systems to exhibit antineoplastic activity. Further laboratory and clinical research is needed to clarify the mechanism of action of somatostatin analogues as antineoplastics, and to determine if the encouraging preclinical results will lead to novel endocrine approaches to the treatment of breast cancer.

 

 

About this publication.

 

See also Somatostatin in oncology, the overlooked evidences.